GUMDROP : A Randomized, Open-Label, Phase 3 Study of BMS-936558 vs. Everolimus in Subjects With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy

Created by Nancy Dawson, last modified on Jan 15, 2013

Description:

The purpose of the study is to compare the clinical benefit, as measured by duration of overall survival, of BMS-936558 vs. Everolimus in subjects with advanced or metastatic clear-cell renal cell carcinoma who have received prior anti-angiogenic therapy

Link:

Link to study in ClinicalTrials.gov

Site:

Georgetown University Hospital

Principal Investigator:

Dr. Nancy Dawson